Standing Orders for Administering Td/Tdap Vaccine to Adults
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Safety of Immunization During Pregnancy a Review of the Evidence
Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. -
Pneumococcal Vaccine
Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal Disease • 2nd most common cause of vaccine preventable death in the US • Major Syndromes – Pneumonia – Bacteremia – Meningitis Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 2010 (ORIG) Vaccine Target • Polysaccharide capsule allows bacteria to resist phagocytosis • Antibodies to capsule facilitate phagocytosis • >90 different pneumococcal capsular serotypes • Vaccines contain most common serotypes causing disease Pneumococcal Vaccines Pneumococcal Vaccines • Pneumococcal polysaccharide vaccine (PPSV23; Pneumovax) – Contains capsular polysaccharides – 23 most commonly infecting serotypes • Cause 60% of all pneumococcal infections in adults – Not recommended for children <2 due to poor immunogenicity of polysaccharides Pneumococcal Vaccines • Pneumococcal conjugate vaccine (PCV13, Prevnar) – Polysaccharides linked to nontoxic protein • higher antigenicity – Stimulates mucosal antibody • Eliminates nasal carriage in young children • Herd effect in adults – Reduction in PCV7 serotype disease >90% Prevnar 13 • 2000 - PCV7 approved for infants toddlers • 2010 - PCV13 recommended for infants and toddlers • 2012 – ACIP recommended PCV13 for high- risk adults • 2014 – recommended for adults >65 • 2018 – ACIP will revisit PCV13 use in adults – Childhood vaccines may eliminate -
Summary Guide to Tetanus Prophylaxis in Routine Wound Management
Summary Guide to Tetanus Prophylaxis in Routine Wound Management ASSESS WOUND A clean, minor wound All other wounds (contaminated with dirt, feces, saliva, soil; puncture wounds; avulsions; wounds resulting from flying or crushing objects, animal bites, burns, frostbite) Has patient completed a primary Has patient completed a primary tetanus diphtheria series?1, 7 tetanus diphtheria series?1, 7 No/Unknown Yes No/Unknown Yes Administer vaccine today.2,3,4 Was the most recent Administer vaccine and Was the most Instruct patient to complete dose within the past tetanus immune gobulin recent dose within series per age-appropriate 10 years? (TIG) now.2,4,5,6,7 the past 5 years?7 vaccine schedule. No Yes No Yes Vaccine not needed today. Vaccine not needed today. Administer vaccine today.2,4 2,4 Patient should receive next Administer vaccine today. Patient should receive next Patient should receive next dose Patient should receive next dose dose at 10-year interval after dose at 10-year interval after per age-appropriate schedule. per age-appropriate schedule. last dose. last dose. 1 A primary series consists of a minimum of 3 doses of tetanus- and diphtheria- 4 Tdap* is preferred for persons 11 through 64 years of age if using Adacel* or 10 years of containing vaccine (DTaP/DTP/Tdap/DT/Td). age and older if using Boostrix* who have never received Tdap. Td is preferred to tetanus 2 Age-appropriate vaccine: toxoid (TT) for persons 7 through 9 years, 65 years and older, or who have received a • DTaP for infants and children 6 weeks up to 7 years of age (or DT pediatric if Tdap previously. -
Systematic Booster After Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure
Article Systematic Booster after Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure Perrine Parize 1,*, Jérémie Sommé 2 , Laura Schaeffer 3, Florence Ribadeau-Dumas 1, Sheherazade Benabdelkader 1, Agnès Durand 4, Arnaud Tarantola 1, Johann Cailhol 5, Julia Goesch 5, Lauriane Kergoat 1 , Anne-Sophie Le Guern 6, Marie-Laurence Mousel 2, Laurent Dacheux 1 , Paul-Henri Consigny 5, Arnaud Fontanet 3,7, Beata Francuz 2 and Hervé Bourhy 1 1 Institut Pasteur, Unit Lyssavirus Epidemiology and Neuropathology, National Reference Center for Rabies and WHO Collaborating Centre for Reference and Research on Rabies, 75015 Paris, France; fl[email protected] (F.R.-D.); [email protected] (S.B.); [email protected] (A.T.); [email protected] (L.K.); [email protected] (L.D.); [email protected] (H.B.) 2 Institut Pasteur, Occupational Health Department, 75015 Paris, France; [email protected] (J.S.); [email protected] (M.-L.M.); [email protected] (B.F.) 3 Institut Pasteur, Emerging Diseases Epidemiology Unit, Centre for Global Health Research and Education, 75015 Paris, France; [email protected] (L.S.); [email protected] (A.F.) 4 Laboratoire Cerballiance, 75017 Paris, France; [email protected] 5 Citation: Parize, P.; Sommé, J.; Institut Pasteur, Centre Médical, Centre d’Infectiologie Necker-Pasteur, 75015 Paris, France; Schaeffer, L.; Ribadeau-Dumas, F.; [email protected] (J.C.); [email protected] (J.G.); [email protected] (P.-H.C.) 6 Benabdelkader, S.; Durand, A.; Institut Pasteur, Laboratory of the Medical Center, 75015 Paris, France; [email protected] 7 Conservatoire National des Arts et Métiers, 75003 Paris, France Tarantola, A.; Cailhol, J.; Goesch, J.; * Correspondence: [email protected]; Tel.: +33-140-613-436 Kergoat, L.; et al. -
YF-VAX® Rx Only AHFS Category
YF-VAX® Rx Only Laboratory Personnel AHFS Category: 80:12 Laboratory personnel who handle virulent yellow fever virus or concentrated preparations Rx only of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect Yellow Fever Vaccine contact or by aerosols. (14) DESCRIPTION CONTRAINDICATIONS ® Hypersensitivity YF-VAX , Yellow Fever Vaccine, for subcutaneous use, is prepared by culturing the YF-VAX is contraindicated in anyone with a history of acute hypersensitivity reaction to any 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken component of the vaccine. (See DESCRIPTION section.) Because the yellow fever virus embryos. The vaccine contains sorbitol and gelatin as a stabilizer, is lyophilized, and is used in the production of this vaccine is propagated in chicken embryos, do not administer hermetically sealed under nitrogen. No preservative is added. Each vial of vaccine is YF-VAX to anyone with a history of acute hypersensitivity to eggs or egg products due to supplied with a separate vial of sterile diluent, which contains Sodium Chloride Injection a risk of anaphylaxis. Less severe or localized manifestations of allergy to eggs or to USP – without a preservative. YF-VAX is formulated to contain not less than 4.74 log10 feathers are not contraindications to vaccine administration and do not usually warrant plaque forming units (PFU) per 0.5 mL dose throughout the life of the product. Before vaccine skin testing. (See PRECAUTIONS section, Testing for Hypersensitivity Re- reconstitution, YF-VAX is a pinkish color. After reconstitution, YF-VAX is a slight pink-brown actions subsection.) Generally, persons who are able to eat eggs or egg products may suspension. -
Vaccines 101 the Very Last Day That I Was a Pediatric Resident. Um, Many
Vaccines 101 The very last day that I was a pediatric resident. Um, many years ago, a toddler walked into the emergency room and uh, and progressively got sicker and sicker. That's Dr. Katherine Edwards, a world expert in pediatric infectious disease in vaccinology. She's also a professor of pediatrics at Vanderbilt university and she's been working on vaccines for 40 years. I did a spinal tap on her and realized that she had Haemophilus influenza, typ e B meningitis, Haemophilus influenza, type B or HIB is it bacteria normally found in our nose and throat that can lead to very serious life threatening infections and no matter what I did in that day and into the night in terms of prompt antibiotics and she'd just been sick a few hours and, and fluids and all the, you know, ventilators and all the best things that modern medicine, she died, the vaccine for hip was not available until the 1990s. And until it did become available, hip disease affected approximately 25,000 children each year with things like meningitis, pneumonia, and bloodstream infections. And at that time in the hospital that I was practicing at any one time, there were generally five or six patients that had Haemophilus meningitis or invasive disease or some complication of this particular infection. And we knew that from the basic science that if you had antibody to the capsule or to the coat of the organism, that you were protected from disease. But we really didn't know how to make little kids make antibody. -
Vaccines for Preteens
| DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe. -
COVID-19 Vaccination Programme: Information for Healthcare Practitioners
COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1. -
Commonly Administered Vaccines
Commonly Administered Vaccines CPT CVX Vaccine Type Brand Name Manufacturer PhilaVax Display Name Description Code Code Combination Vaccines Diptheria, tetanus toxoids and acellular pertussis vaccine, Hepati- DTaP-HepB-IPV Pediarix® GlaxoSmithKline 90723 110 DTaP-HepB-IPV tis B and poliovirus vaccine, inactivated Diptheria, tetanus toxoids and acellular pertussis vaccine and DTaP-Hib TriHIBit® Sanofi Pasteur 90721 50 DTaP-Hib (TriHIBit) Haemophilus influenzae type b conjugate vaccine Diptheria, tetanus toxoids and acellular pertussis vaccine, Hae- DTaP-Hib-IPV Pentacel® Sanofi Pasteur 90698 120 DTaP-Hib-IPV mophilus influenzae type b, and poliovirus vaccine, inactivated Diptheria, tetanus toxoids and acellular pertussis vaccine, and DTaP-IPV Kinrix® GlaxoSmithKline 90696 130 DTaP-IPV (KINRIX) poliovirus vaccine, inactivated HepA-HepB TWINRIX® GlaxoSmithKline 90636 104 HepA/B (TWINRIX) Hepatisis A and Hepatitis B vaccine, adult dosage Hepatitis B and Hemophilus influenza b vaccine, for intramuscular HepB-Hib Comvax® Merck 90748 51 Hib-Hep B (COMVAX) use Haemophilus influenza b and meningococcal sero groups C and Y MeningC/Y-Hib Menhibrix® GlaxoSmithKline 90644 148 Meningococcal-Hib vaccine, 4 dose series Diphtheria, Tetanus and Pertussis DTaP Infanrix® GlaxoSmithKline 90700 20 DTaP (INFANRIX) Diptheria, tetanus toxoids and acellular pertussis vaccine DTaP, 5 Pertussis Antigens Daptacel® Sanofi Pasteur 90700 106 DTaP (DAPTACEL) Diptheria, tetanus toxoids and acellular pertussis vaccine Tetanus toxoid, reduced diphtheria toxoid, and acellular -
Vaccine Hesitancy
Vaccine Hesitancy Dr Brenda Corcoran National Immunisation Office Presentation Outline An understanding of the following principles: • Overview of immunity • Different types of vaccines and vaccine contents • Vaccine failures • Time intervals between vaccine doses • Vaccine overload • Adverse reactions • Herd immunity Immunity Immunity • The ability of the human body to protect itself from infectious disease The immune system • Cells with a protective function in the – bone marrow – thymus – lymphatic system of ducts and nodes – spleen –blood Types of immunity Source: http://en.wikipedia.org/wiki/Immunological_memory Natural (innate) immunity Non-specific mechanisms – Physical barriers • skin and mucous membranes – Chemical barriers • gastric and digestive enzymes – Cellular and protein secretions • phagocytes, macrophages, complement system ** No “memory” of protection exists afterwards ** Passive immunity – adaptive mechanisms Natural • maternal transfer of antibodies to infant via placenta Artificial • administration of pre- formed substance to provide immediate but short-term protection (antitoxin, antibodies) Protection is temporary and wanes with time (usually few months) Active immunity – adaptive mechanisms Natural • following contact with organism Artificial • administration of agent to stimulate immune response (immunisation) Acquired through contact with an micro-organism Protection produced by individual’s own immune system Protection often life-long but may need boosting How vaccines work • Induce active immunity – Immunity and immunologic memory similar to natural infection but without risk of disease • Immunological memory allows – Rapid recognition and response to pathogen – Prevent or modify effect of disease Live attenuated vaccines Weakened viruses /bacteria – Achieved by growing numerous generations in laboratory – Produces long lasting immune response after one or two doses – Stimulates immune system to react as it does to natural infection – Can cause mild form of the disease (e.g. -
Ensuring the World's Poorest Children Benefit from Lifesaving Vaccines
WHAT WE’RE LEARNING Ensuring the World’s Poorest Children Benefit from Lifesaving Vaccines “Supporting children’s immunization is undoubtedly the best investment we’ve ever made.” —Bill and Melinda Gates Program Area pertussis) vaccine. When GAVI was The Challenge launched, 71 percent of the world’s Global Health Most people in rich nations do not children were receiving DTP vaccine. realize how difficult it is simply to By 2004, the rate had increased to survive early childhood in many parts Our Goal 78 percent. of the world. Every year, more than Prevent needless deaths in the world’s GAVI has concentrated the greatest 10 million children are buried before poorest countries by increasing access percentage of its resources on speeding they reach their fifth birthday. Of these, to basic vaccines and speeding the the introduction of newer, more about 1.4 million die from diseases that introduction of new vaccines. expensive vaccines, including those for existing vaccines can prevent—including hepatitis B, Haemophilus influenzae B measles, pertussis, and tetanus. Another Our Progress in Brief (Hib), and yellow fever. The vaccine 1.1 million die from diseases for which The Global Alliance for Vaccines for hepatitis B, for example, had been we will soon have vaccines. Because and Immunization (GAVI), which widely used in rich countries for childhood death is so frequent, parents the foundation helped to launch in 20 years but was severely underutilized in some countries in Africa and Asia 1999, has made significant progress. in the developing world because of a don’t even name their babies until they Children’s immunization is no longer a lack of political will and the vaccine’s reach several months of age. -
The Challenge of Achieving Universal Access to Vaccines
Keynote Address: The Challenge of Achieving Universal Access to Vaccines WIPO & AMF Seth Berkley M.D, CEO 8 November 2017 www.gavi.org 1 Vaccine landscape WIPO 8 November 2017 The world before vaccines Examples of major disease outbreaks Polio Cholera New York pandemic 1916 Europe 6,000 deaths 1829-1851 >200,000 deaths Yellow fever Philadelphia Smallpox 1793 epidemic >5,000 India deaths 1974 15,000 deaths Flu pandemic 1918-1920 > 50-100 million deaths worldwide WIPO 8 November 2017 History of vaccine development Source: Delaney et.al. 2014 WIPO 8 November 2017 Cumulative number of vaccines developed licensed 50+ vaccines Lyme OspA, protein (1998) Tuberculosis (Bacille Calmette-Guérin) Pneumococcal conjugate, heptavalent* (2000) 1927 Typhus Varicella (1995) Meningococcal quadrivalent conjugates* (2005) Japanese encephalitis (Vera-cell) (2009) 1938 Cholera (recombinant Toxin B) # (1993) Cholera (WC only) (2009) Tetanus toxoid Cholera (WC-rBC) (1991) Human papillomavirus recombinant bivalent (2009) Influenza H. influenzaeconjugate* (1987) Quadrivalent influenza vaccines (2012) Typhoid Cholera Pertussis 1936 Meningococcal C and Y and 1886 1896 1926 H. influenza type B polysaccharide (1985) Haemophilusinfluenza type b (2012) Adenovirus (1980) Meningococcal B (2013) Smallpox Diphtheria Yellow Rabies, cell culture (1980) Influenza vaccine (baculovirus) (2013) 1798 toxoid Fever Typhoid conjugate vaccine (2013) Rabies Plague Meningococcal polysaccharides (1974) 1923 1935 Human papillomavirus, 9-valent (2014) 1885 Rubella, live (1969) 1897 vaccines